BioCentury
ARTICLE | Clinical News

AKB-6548: Phase I started

September 21, 2009 7:00 AM UTC

Akebia began a double-blind, placebo-controlled, single ascending-dose, U.S. Phase I trial to evaluate oral AKB-6548 in up to 48 healthy volunteers. ...